Fig. 5

GMCSF-MOG was superior to GMCSF-NFM for eliciting persistence of a CD44^high Tcon phenotype. a–d 2D2-FIG mice were vaccinated with 4 nmol of GMCSF-MOG (n = 5), 4 nmol of GMCSF-NFM (n = 5), or with saline (n = 5). PBMCs were analyzed on days 5, 12, and 19 for CD3, CD4, CD44, and FOXP3 expression. a–c The day 0 time point was derived from the CD44 expression of CD3⁺ CD4⁺ T cells from naïve 2D2-FIG mice (n = 23). Shown are percentages of a CD44^high T cells, b CD44^high Tcons, and c CD44^high Tregs of gated CD3⁺ CD4⁺ T cells on days 0, 5, 12, and 19. Shown in d are the percentage of CD62L^low T cells of gated CD44^high CD3⁺ CD4⁺ T cells on day 5, 12, and 19. Shown in e are representative dot plots of CD44 (y-axis) and FOXP3 (x-axis) expression of CD4⁺ CD3⁺ T cells on day 5. These data are representative of three independent experiments. Statistical significance was analyzed using a one-way ANOVA. Shown in a, b and d are significant differences between the groups GMCSF-MOG, GMCSF-NFM, and saline, and c statistical differences comparing GMCSF-MOG treatment to both GMCSF-NFM and saline. (*p < 0.05, **p < 0.01, ***p < 0.001). d Asterisks apply to all comparisons at a given timepoint. Error bars represent SEM